(DGX) Quest Diagnostics - Ratings and Ratios
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US74834L1008
Clinical Testing, Pathology, Risk Assessment, Health IT
Dividends
| Dividend Yield | 1.73% |
| Yield on Cost 5y | 2.83% |
| Yield CAGR 5y | 7.58% |
| Payout Consistency | 96.3% |
| Payout Ratio | 32.6% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 20.9% |
| Value at Risk 5%th | 30.4% |
| Relative Tail Risk | -11.37% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.52 |
| Alpha | 6.90 |
| CAGR/Max DD | 0.42 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.430 |
| Beta | 0.253 |
| Beta Downside | 0.219 |
| Drawdowns 3y | |
|---|---|
| Max DD | 22.00% |
| Mean DD | 7.70% |
| Median DD | 6.99% |
Description: DGX Quest Diagnostics October 16, 2025
Quest Diagnostics Inc. (NYSE:DGX) is a U.S.-based provider of diagnostic testing and related information services, operating under the Quest Diagnostics brand and several subsidiaries (AmeriPath, Dermpath Diagnostics, ExamOne, Quanum). It offers a full spectrum of laboratory services-from routine blood work to advanced molecular and anatomic pathology-delivered through a nationwide network of labs, patient service centers, mobile phlebotomy, and digital platforms to physicians, hospitals, insurers, employers, and consumers.
Key metrics and industry drivers: • FY 2023 revenue reached approximately **$12.5 billion**, with a **~7 % operating margin**, reflecting steady demand for high-margin specialty testing. • The company’s growth is bolstered by the **aging U.S. population** and rising prevalence of chronic diseases, which increase utilization of lab services. • Medicare reimbursement reforms and the shift toward **outpatient and at-home testing** are accelerating demand for Quest’s mobile phlebotomy and digital health solutions, while also pressuring pricing dynamics.
For a deeper quantitative analysis, you may find ValueRay’s data platform useful for evaluating Quest Diagnostics’ valuation and risk profile.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income (969.0m TTM) > 0 and > 6% of Revenue (6% = 651.0m TTM) |
| FCFTA 0.09 (>2.0%) and ΔFCFTA 2.24pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 2.52% (prev 5.57%; Δ -3.05pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.12 (>3.0%) and CFO 1.89b > Net Income 969.0m (YES >=105%, WARN >=100%) |
| Net Debt (5.95b) to EBITDA (2.14b) ratio: 2.78 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.13 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (113.0m) change vs 12m ago 0.0% (target <= -2.0% for YES) |
| Gross Margin 33.30% (prev 32.77%; Δ 0.53pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 67.20% (prev 59.27%; Δ 7.93pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 5.60 (EBITDA TTM 2.14b / Interest Expense TTM 282.0m) >= 6 (WARN >= 3) |
Altman Z'' 3.91
| (A) 0.02 = (Total Current Assets 2.41b - Total Current Liabilities 2.13b) / Total Assets 16.20b |
| (B) 0.61 = Retained Earnings (Balance) 9.84b / Total Assets 16.20b |
| (C) 0.10 = EBIT TTM 1.58b / Avg Total Assets 16.15b |
| (D) 1.11 = Book Value of Equity 9.80b / Total Liabilities 8.82b |
| Total Rating: 3.91 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 66.19
| 1. Piotroski 8.0pt |
| 2. FCF Yield 5.07% |
| 3. FCF Margin 12.84% |
| 4. Debt/Equity 0.88 |
| 5. Debt/Ebitda 2.78 |
| 6. ROIC - WACC (= 3.85)% |
| 7. RoE 13.75% |
| 8. Rev. Trend 30.46% |
| 9. EPS Trend -29.56% |
What is the price of DGX shares?
As of December 03, 2025, the stock is trading at USD 182.55 with a total of 1,177,547 shares traded.
Over the past week, the price has changed by -5.09%, over one month by +2.07%, over three months by +2.61% and over the past year by +15.16%.
Over the past week, the price has changed by -5.09%, over one month by +2.07%, over three months by +2.61% and over the past year by +15.16%.
Is DGX a buy, sell or hold?
Quest Diagnostics has received a consensus analysts rating of 3.89.
Therefore, it is recommended to buy DGX.
- Strong Buy: 8
- Buy: 1
- Hold: 10
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the DGX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 197.3 | 8.1% |
| Analysts Target Price | 197.3 | 8.1% |
| ValueRay Target Price | 200.7 | 9.9% |
DGX Fundamental Data Overview November 27, 2025
Market Cap USD = 21.51b (21.51b USD * 1.0 USD.USD)
P/E Trailing = 22.3663
P/E Forward = 18.1159
P/S = 1.9824
P/B = 2.921
P/EG = 1.5353
Beta = 0.623
Revenue TTM = 10.85b USD
EBIT TTM = 1.58b USD
EBITDA TTM = 2.14b USD
Long Term Debt = 5.17b USD (from longTermDebt, last quarter)
Short Term Debt = 677.0m USD (from shortTermDebt, last quarter)
Debt = 6.38b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 5.95b USD (from netDebt column, last quarter)
Enterprise Value = 27.46b USD (21.51b + Debt 6.38b - CCE 432.0m)
Interest Coverage Ratio = 5.60 (Ebit TTM 1.58b / Interest Expense TTM 282.0m)
FCF Yield = 5.07% (FCF TTM 1.39b / Enterprise Value 27.46b)
FCF Margin = 12.84% (FCF TTM 1.39b / Revenue TTM 10.85b)
Net Margin = 8.93% (Net Income TTM 969.0m / Revenue TTM 10.85b)
Gross Margin = 33.30% ((Revenue TTM 10.85b - Cost of Revenue TTM 7.24b) / Revenue TTM)
Gross Margin QoQ = 33.70% (prev 34.15%)
Tobins Q-Ratio = 1.70 (Enterprise Value 27.46b / Total Assets 16.20b)
Interest Expense / Debt = 1.08% (Interest Expense 69.0m / Debt 6.38b)
Taxrate = 22.92% (77.0m / 336.0m)
NOPAT = 1.22b (EBIT 1.58b * (1 - 22.92%))
Current Ratio = 1.13 (Total Current Assets 2.41b / Total Current Liabilities 2.13b)
Debt / Equity = 0.88 (Debt 6.38b / totalStockholderEquity, last quarter 7.26b)
Debt / EBITDA = 2.78 (Net Debt 5.95b / EBITDA 2.14b)
Debt / FCF = 4.27 (Net Debt 5.95b / FCF TTM 1.39b)
Total Stockholder Equity = 7.05b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.98% (Net Income 969.0m / Total Assets 16.20b)
RoE = 13.75% (Net Income TTM 969.0m / Total Stockholder Equity 7.05b)
RoCE = 12.91% (EBIT 1.58b / Capital Employed (Equity 7.05b + L.T.Debt 5.17b))
RoIC = 9.40% (NOPAT 1.22b / Invested Capital 12.94b)
WACC = 5.55% (E(21.51b)/V(27.89b) * Re(6.95%) + D(6.38b)/V(27.89b) * Rd(1.08%) * (1-Tc(0.23)))
Discount Rate = 6.95% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
[DCF Debug] Terminal Value 78.65% ; FCFE base≈1.25b ; Y1≈1.28b ; Y5≈1.42b
Fair Price DCF = 225.3 (DCF Value 25.07b / Shares Outstanding 111.2m; 5y FCF grow 2.43% → 3.0% )
EPS Correlation: -29.56 | EPS CAGR: -6.39% | SUE: 1.93 | # QB: 4
Revenue Correlation: 30.46 | Revenue CAGR: 0.69% | SUE: 3.44 | # QB: 2
EPS next Quarter (2026-03-31): EPS=2.36 | Chg30d=+0.018 | Revisions Net=+4 | Analysts=11
EPS next Year (2026-12-31): EPS=10.37 | Chg30d=+0.046 | Revisions Net=+7 | Growth EPS=+5.7% | Growth Revenue=+3.6%
P/E Trailing = 22.3663
P/E Forward = 18.1159
P/S = 1.9824
P/B = 2.921
P/EG = 1.5353
Beta = 0.623
Revenue TTM = 10.85b USD
EBIT TTM = 1.58b USD
EBITDA TTM = 2.14b USD
Long Term Debt = 5.17b USD (from longTermDebt, last quarter)
Short Term Debt = 677.0m USD (from shortTermDebt, last quarter)
Debt = 6.38b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 5.95b USD (from netDebt column, last quarter)
Enterprise Value = 27.46b USD (21.51b + Debt 6.38b - CCE 432.0m)
Interest Coverage Ratio = 5.60 (Ebit TTM 1.58b / Interest Expense TTM 282.0m)
FCF Yield = 5.07% (FCF TTM 1.39b / Enterprise Value 27.46b)
FCF Margin = 12.84% (FCF TTM 1.39b / Revenue TTM 10.85b)
Net Margin = 8.93% (Net Income TTM 969.0m / Revenue TTM 10.85b)
Gross Margin = 33.30% ((Revenue TTM 10.85b - Cost of Revenue TTM 7.24b) / Revenue TTM)
Gross Margin QoQ = 33.70% (prev 34.15%)
Tobins Q-Ratio = 1.70 (Enterprise Value 27.46b / Total Assets 16.20b)
Interest Expense / Debt = 1.08% (Interest Expense 69.0m / Debt 6.38b)
Taxrate = 22.92% (77.0m / 336.0m)
NOPAT = 1.22b (EBIT 1.58b * (1 - 22.92%))
Current Ratio = 1.13 (Total Current Assets 2.41b / Total Current Liabilities 2.13b)
Debt / Equity = 0.88 (Debt 6.38b / totalStockholderEquity, last quarter 7.26b)
Debt / EBITDA = 2.78 (Net Debt 5.95b / EBITDA 2.14b)
Debt / FCF = 4.27 (Net Debt 5.95b / FCF TTM 1.39b)
Total Stockholder Equity = 7.05b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.98% (Net Income 969.0m / Total Assets 16.20b)
RoE = 13.75% (Net Income TTM 969.0m / Total Stockholder Equity 7.05b)
RoCE = 12.91% (EBIT 1.58b / Capital Employed (Equity 7.05b + L.T.Debt 5.17b))
RoIC = 9.40% (NOPAT 1.22b / Invested Capital 12.94b)
WACC = 5.55% (E(21.51b)/V(27.89b) * Re(6.95%) + D(6.38b)/V(27.89b) * Rd(1.08%) * (1-Tc(0.23)))
Discount Rate = 6.95% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
[DCF Debug] Terminal Value 78.65% ; FCFE base≈1.25b ; Y1≈1.28b ; Y5≈1.42b
Fair Price DCF = 225.3 (DCF Value 25.07b / Shares Outstanding 111.2m; 5y FCF grow 2.43% → 3.0% )
EPS Correlation: -29.56 | EPS CAGR: -6.39% | SUE: 1.93 | # QB: 4
Revenue Correlation: 30.46 | Revenue CAGR: 0.69% | SUE: 3.44 | # QB: 2
EPS next Quarter (2026-03-31): EPS=2.36 | Chg30d=+0.018 | Revisions Net=+4 | Analysts=11
EPS next Year (2026-12-31): EPS=10.37 | Chg30d=+0.046 | Revisions Net=+7 | Growth EPS=+5.7% | Growth Revenue=+3.6%
Additional Sources for DGX Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle